Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 [Yahoo! Finance]
Lipocine Inc. (LPCN)
Last lipocine inc. earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.lipocine.com
Company Research
Source: Yahoo! Finance
study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver ("EASL") Congress, to take place June 5 to 8, 2024 in Milan, Italy Presentation Details Title Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy ("HE") in patients with cirrhosis: a 52-week phase 2 randomized clinical trial Presenter: Dr. Arun J. Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University Session Title: Late Breaker Session Date and Time: Saturday, 8 June, 14:00 - 15:30 CEST Presentation Time: 15.15 CEST Location Gold Room Abstract Number: LP139 About LPCN 1148 Lipocine is currently evaluating LPCN 1148 comprising testosterone laurate ("TL") for the management of decompensated cirrhosis. The Company believes LPCN 1148 targets unmet needs for patients with cirrhosis including improvements in sarcopenia and quality of life,
Show less
Read more
Impact Snapshot
Event Time:
LPCN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPCN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPCN alerts
High impacting Lipocine Inc. news events
Weekly update
A roundup of the hottest topics
LPCN
News
- Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 [Yahoo! Finance]Yahoo! Finance
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024PR Newswire
- Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024PR Newswire
- Lipocine Inc. (NASDAQ: LPCN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
LPCN
Earnings
- 11/8/23 - Miss
LPCN
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/8/24 - Form 8-K
- LPCN's page on the SEC website